Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with an advanced solid tumour cancer (one that has spread, cannot be removed by surgery, or has come back) that is not a brain tumour that started in the brain or spinal cord
- Your cancer has gotten worse during or after your most recent cancer treatment, or you were unable to tolerate that treatment
- Your cancer can be measured on scans, following standard measurement guidelines
- You are generally well enough to carry out light activity and care for yourself (your doctor will assess this)
- You have previously received standard approved treatments that were available to you, unless those treatments were not suitable or you chose not to have them
- You have not taken part in another experimental drug trial within the past 3 weeks (or 5 half-lives of that drug, whichever is shorter, with a minimum of 2 weeks) before starting this trial
- Your doctor expects you to live for at least 3 more months
- Patients with a known BRCA2 gene mutation that stops the gene from working normally may be given extra consideration for joining
Who may not be able to join:
- You are taking steroid tablets (such as prednisone) at a dose higher than 10 mg per day on an ongoing basis (low-dose steroids for a medical condition, or inhaled, skin, or eye steroids are generally allowed)
- You have had full-dose radiotherapy within the last 6 weeks, or lower-dose (palliative) radiotherapy within the last 2 weeks
- You have brain tumour spread (metastases) that are causing symptoms or getting worse — stable, previously treated brain metastases may be allowed if they have not changed for at least 4 weeks
- You have a digestive system condition that could affect how your body absorbs the study drug, or you have had a bowel blockage in the last 6 months, or fluid drained from your abdomen within the last 8 weeks
- You have spreading cancer in the membranes around the brain or spinal cord (leptomeningeal disease) that is active and worsening (confirm with trial site)
- You have certain heart rhythm abnormalities detected on an ECG, a personal or family history of a specific inherited heart condition (long QT syndrome), are taking medications known to affect heart rhythm, or have other heart rhythm risk factors (confirm with trial site)
- You have had a heart attack or unstable chest pain within the last 6 months, or have significant heart problems such as uncontrolled high blood pressure or heart failure
- You have an active or long-term serious infection, including tuberculosis, hepatitis B, hepatitis C, or HIV-related illness — some well-controlled infections with undetectable virus levels may still be allowed (confirm with trial site)
- You have uncontrolled kidney disease, pancreas disease, or liver disease (some liver conditions may still be allowed — confirm with trial site)
- You have had another cancer in the last 2 years that needed treatment, unless it was an early-stage cancer treated with the aim of curing it (such as certain skin cancers or early bladder cancer) and you no longer need ongoing chemotherapy
- You are currently taking certain medications including proton pump inhibitors (such as omeprazole), or certain drugs that strongly affect how the liver breaks down medications (confirm with trial site)
- You are currently taking warfarin (Coumadin) or similar blood-thinning medications of the same type
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniel McCormick, 858 Therapeutics, Inc.
Phone: (858) 987-8380
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To characterize the safety and tolerability of ETX-19477, the maximum tolerated dose (MTD) and/or RP2D of ETX-19477
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.